The value of the ADF strategy evaluated here is based on a strategy of 'FDA conversion': e.g. removal of non-AD generics from the market.
Opioid Conflicts Majority Staff Report · page 44 of 53
The slide contains a pull-quote highlighting the core strategy and detailed footnotes citing internal McKinsey documents and external reports.
Consulting deck · appendix_disclosure · summarize · overcrowded density
Slide locked Sign in to view
Slide schematic 6/6
paragraph 4/4 quote 1/1 source-note 1/1
Components 6
paragraph paragraph paragraph paragraph pull-quote source-note
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 1
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.